An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Public ClinicalTrials.gov record NCT02617589. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate patients with glioblastoma that is MGMT-unmethylated (the MGMT gene is not altered by a chemical change). Patients will receive Nivolumab every two weeks in addition to radiation therapy, and then every four weeks. They will be compared to patients receiving standard therapy with temozolomide in addition to radiation therapy.
Study identification
- NCT ID
- NCT02617589
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 560 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 1, 2016 (Actual)
- Primary completion
- Jan 17, 2019 (Actual)
- Completion
- Mar 4, 2022 (Actual)
- Last update posted
- Mar 28, 2023
2016 – 2022
United States locations
- U.S. sites
- 37
- U.S. states
- 24
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294-3410 | — |
| Local Institution - 0083 | Phoenix | Arizona | 85013 | — |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| Local Institution - 0019 | Los Angeles | California | 90095-1769 | — |
| Sutter Institute For Medical Research | Sacramento | California | 95816 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| The Regents of the University of California, San Francisco | San Francisco | California | 94143-0372 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| University Of Miami Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University - Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| The University Of Chicago | Chicago | Illinois | 60637 | — |
| University Of Kansas Medical Center | Westwood | Kansas | 66205 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Johns Hopkins University School Of Medicine | Baltimore | Maryland | 21287 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02215 | — |
| Local Institution - 0006 | Detroit | Michigan | 48202 | — |
| Washington University School OF Medicine-Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| JFK Medical Center | Edison | New Jersey | 08820 | — |
| Local Institution - 0064 | Hackensack | New Jersey | 07601 | — |
| Columbia University Medical Center (Cumc) | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Preston Robert Tisch Brain Tumor Center at Duke University | Durham | North Carolina | 27710 | — |
| Local Institution - 0010 | Cleveland | Ohio | 44195 | — |
| Local Institution - 0095 | Columbus | Ohio | 43210 | — |
| Local Institution - 0132 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 0007 | Philadelphia | Pennsylvania | 19107 | — |
| Medical University Of South Carolina | Charleston | South Carolina | 29425 | — |
| Local Institution - 0090 | Chattanooga | Tennessee | 37404 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| University Of Texas Southwestern Medical Center | Dallas | Texas | 75390-8852 | — |
| University Of Texas Md Anderson Cancer Ctr | Houston | Texas | 77030 | — |
| Local Institution - 0068 | Salt Lake City | Utah | 84112 | — |
| Swedish Neuroscience Institute | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02617589, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 28, 2023 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02617589 live on ClinicalTrials.gov.